These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32201021)

  • 1. 4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
    He X; Gao Y; Hui Z; Shen G; Wang S; Xie T; Ye XY
    Bioorg Med Chem Lett; 2020 May; 30(10):127109. PubMed ID: 32201021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
    Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
    Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
    Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
    J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.
    Yan J; Gu Y; Sun Y; Zhang Z; Zhang X; Wang X; Wu T; Zhao D; Cheng M
    Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100102. PubMed ID: 33987875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
    Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
    Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
    Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A
    Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
    Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
    Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
    Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
    Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
    Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
    Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
    Ren C; Lin Y; Liu X; Yan D; Xu X; Zhu D; Kong L; Han C
    Bioorg Chem; 2021 Mar; 108():104666. PubMed ID: 33550070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
    Zhou C; Kang D; Xu Y; Zhang L; Zha X
    Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
    Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
    Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
    J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1.
    Mould DP; Bremberg U; Jordan AM; Geitmann M; McGonagle AE; Somervaille TCP; Spencer GJ; Ogilvie DJ
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4755-4759. PubMed ID: 28927796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.
    Wang S; Zhao LJ; Zheng YC; Shen DD; Miao EF; Qiao XP; Zhao LJ; Liu Y; Huang R; Yu B; Liu HM
    Eur J Med Chem; 2017 Jan; 125():940-951. PubMed ID: 27769034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.